ROSEN Law Firm Encourages ImmunityBio Investors to Seek Counsel

The global law firm is investigating potential securities claims on behalf of ImmunityBio shareholders.

Mar. 29, 2026 at 2:36pm

Got story updates? Submit your updates here. ›

ROSEN, a global and leading law firm, is encouraging investors who suffered losses investing in ImmunityBio, Inc. to seek legal counsel. The firm is investigating potential securities claims on behalf of ImmunityBio shareholders.

Why it matters

ImmunityBio is a clinical-stage immunotherapy company focused on treatments for cancer and infectious diseases. The ROSEN law firm's investigation suggests there may be issues with the company's disclosures or actions that have impacted investor returns.

The details

The ROSEN law firm is investigating potential securities claims on behalf of ImmunityBio shareholders. The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • The investigation was announced on March 29, 2026.

The players

ROSEN

A global and leading law firm that is investigating potential securities claims on behalf of ImmunityBio shareholders.

ImmunityBio, Inc.

A clinical-stage immunotherapy company focused on treatments for cancer and infectious diseases.

Got photos? Submit your photos here. ›

What’s next

The ROSEN law firm is encouraging ImmunityBio investors to contact the firm to discuss their legal options.

The takeaway

This investigation by a prominent law firm suggests there may be issues with ImmunityBio's disclosures or actions that have impacted investor returns, highlighting the importance of due diligence and legal counsel for shareholders.